Results for the following 2 drugs: There were no interactions found in our database between Vitamin B12 and warfarinHowever, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.Vitamin B12 is in the drug class vitamins. Vitamin B12 is used to treat the following conditions: B12 Nutritional Deficiency, Pernicious Anemia, Schilling Test, Vitamin B12 Deficiency.Warfarin is a member of the drug class coumarins and indandiones. Warfarin is used to treat the following conditions: Antiphospholipid Syndrome, Chronic Central Venous Catheterization, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis, First Event, Deep Vein Thrombosis, Recurrent Event, Heart Attack, Heart Failure, Prevention of Thromboembolism in Atrial Fibrillation, Prosthetic Heart Valves - Thrombosis Prophylaxis, Prosthetic Heart Valves, Mechanical Valves - Thrombosis Prophylaxis
, Prosthetic Heart Valves, Tissue Valves - Thrombosis Prophylaxis, Protein S Deficiency, Pulmonary Embolism, First Event, Pulmonary Embolism, Recurrent Event, Thromboembolic Stroke Prophylaxis.Vitamin B12 Drug InteractionsVitamin B-12 injection General Consumer InformationWarfarin Drug Interactionswarfarin tablets General Consumer InformationDrug Interactions CheckerDisclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient.
Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist. Drug: folic acid multivitamin Allocation: RandomizedMasking: Double-BlindPrimary Purpose: Prevention Vitamin Intervention for Stroke Prevention Estimated Study Completion Date: Ages Eligible for Study: 35 Years and older (Adult, Senior) Sexes Eligible for Study: Any stroke (non-disabling cerebral infarction, NDCI) < 120 days prior to randomization Symptoms lasting > 24 hrs, or if < 24 hrs, CT or MRI shows new infarction at expected site Modified Rankin score < 3 Homocysteine level > the 25th percentile, ie, 9.5 mol/L for men, and 8.5 mol/L for women Patient compliance with multivitamin during run-in phase > 75% Stroke due to: intracranial hemorrhage, dissection of a cervico-cephalic artery, veno-occlusive disease, drug abuse, vasculitis
CT or MRI shows lesion other than infarction as cause of syndrome Modified Rankin score of 4 or 5 at eligibility Presence of potential sources of cardiogenic emboli: atrial fibrillation, prosthetic cardiac valve, intracardiac thrombus or neoplasm, valvular vegetation Neurologic illness other than stroke that would prevent proper evaluation of recurrent stroke Illness that limits life expectancy to < 2 years Severe congestive heart failure Renal insufficiency requiring dialysis Untreated B12 deficiency or untreated pernicious anemia Uncontrolled hypertension (systolic >185 mm/Hg or diastolic >105 mm/Hg on two readings separated by 5 min.) at eligibility Conditions preventing reliable participation in study: refractory depression, severe cognitive impairment, alcoholism, other substance abuse Medications given within last 30 days that affect homocysteine: methotrexate, tamoxifen, L-dopa, phenytoin, or bile acid sequestrants that can decrease folate levels
Women of childbearing potential Patients receiving active intervention in another trial Patients on multi-vitamins, single B6, or folic acid, unless willing to discontinue and take study supplement Any surgical procedure, invasive cardiac instrumentation, endarterectomy, stent placement, thrombectomy or other endovascular treatment of abnormal carotid artery performed within 30 days prior to randomization or scheduled within 30 days after randomization Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies. Please refer to this study by its ClinicalTrials.gov identifier: NCT00004734 Wake Forest University School of Medicine Winston Salem, North Carolina, United States, 27157-1068
once it starts it is much more difficult to fix compared to not letting it start in the first place. A-fib, when occurring in combination with other cardiovascular risk factors, can increase the risk of stroke sevenfold. This is truly a situation in which an ounce of prevention is worth a pound of cure. Your pulse rate increases when your body needs to move oxygen and nutrition to cells more rapidly. This can be to compensate for increased physical output such as hard work or exercise, as well as emotional stress. Once the stress or increased demands are over, your heart rate returns to its normal baseline If your cardiovascular fitness is in good shape. In situations of declining cardiovascular health your baseline may be a rapid and/or irregular heart beat, which tends to worsen with increased demands of one type or another. Compared to a rapid pulse, A-fib means that the pulse is under electrical dysregulation. At first, this simply may present as a jittery or uncomfortable feeling in your heart or chest.
The problem may be aggravated by increased demands, including exercise. The metabolic conditions that contribute to weight gain and difficulty losing weight are key factors that contribute to the development of A-fib (although any person can develop A-fib). These problems gradually develop over time. In other words, various nutritional deficiencies set the stage for the formation of the problem. Once the problem exists it is not simply a matter of taking a vitamin to fix it immediately, although many nutrients offer support while people manage their cardiovascular health into better condition. A new study found that patients with A-fib have lower levels of DHA compared to those who don’t. This means that those who do not regularly consume DHA, either from dietary or supplemental sources, are more at risk for developing this health problem, which in turn may dramatically increase the risk for stroke. This new study involved 206 dialysis patients with cardiovascular disease.
In this group, those with A-fib (13 percent) had the lowest blood levels of DHA. An intervention of 1.7 grams of fish oil per day over a three month period did not improve the A-fib in this diseased patient population. One of the main points about the data in this study is that it is a lot easier to prevent irregular heart beats in the first place or to aggressively work to improve them when they first become a health problem, compared to improving them once they are occurring in the context of many health problems that have been evolving over a period of time. DHA is a primary anti-inflammatory nutrient for both the structure and function of every cell in your cardiovascular system as well as your nervous system. It is therefore not at all surprising that a lack of DHA would be associated with a problem that involves nerves, arteries, veins, and your heart. Regular intake of DHA is highly advised for many aspects of good health even if you are in good health. Once your health starts slipping, higher amounts of DHA are needed to help right the ship.
For example, I recommend daily DHA intake ranging from 150 mg to 500 mg per day, depending on demands you are under, your general health, and your age. The less stress you are under, the better health you are in, and the younger you are, the lower your dose needs to be for the purpose of preserving good health. Once your health starts to slide, reflected by troubles with metabolism such as weight gain or type 2 diabetes and/or once your cardiovascular profile starts to accumulate risk factors, then you need higher doses of DHA. The range should now be between 500 mg to 2000 mg of DHA per day. In general, the worse your health the more DHA you need. For those who simply want to maximize preservation of good health, a higher dose is probably more beneficial. In the study, patients given a dose of 1.7 grams of fish oil per day for three months did not improve the A-fib. That is partly because the dose of DHA was too low and partly because a lack of DHA was not the only nutrition related problem associated with A-fib.
A dose of 1.7 grams of fish oil contains somewhere between 300 to 400 mg of DHA, which is a dose below the therapeutic threshold for any person with existing cardiovascular disease. A person with A-fib should comprehensively support the problem in three ways: 1) Take a variety of nutrients to reduce inflammation while managing life demands. Increasing intake of DHA is the foundation of such a nutrient plan. 2) Include nerve support nutrition to reduce the effects of inflammatory nerve compounds irritating the heart and electrical system. Increasing magnesium intake is the most basic approach to helping calm nerves. 3) Provide heart tonic nutrition, which has the net effect of helping the heart overcome being punched in the nose by the problem. In this regard, flavonoids contained in hawthorn berry and grape seed extract are top choices. It should be understood that A-fib is highly associated with structural problems in the arteries, which are driven to form in response to excessive ongoing inflammation.
These problems are especially associated with obesity, but can occur based on inflammatory issues of any kind for a person of any weight. In the case of obesity, fat marbleizing in the artery walls and accumulating on the outside of the arteries creates a significant adverse structural change to the arteries. This is the cause of A-fib for the majority of people who have it. The comprehensive nutrients listed above will not immediately fix this problem, but will help keep the lid on how bad the problem is. When a person loses weight, the structural problem within the arteries begins to reverse itself. This takes time to truly fix, but major improvement can be experienced early on once a person establishes the process of weight loss in a healthy way. Any person of any weight who has A-fib must figure out the long-term sources of inflammation and map out a plan for improvement. This is because inflammation in and of itself can make your arteries fatty, even if you are normal weight.
This means that a variety of excessive inflammatory factors could be the actual cause of the problem. Issues can range from high levels of emotional stress to chronic low-grade infections, chronic pain to post traumatic stress disorder, just to give a few common issues. These will vary from person to person. The primary cause of A-fib is likely a collection of various inflammatory issues that have induced changes to the structure of the main arteries and veins around the heart over time. People with problems such as these need enough nutritional support to help out body systems that are under acute stress. And they need to get on a less inflammatory path, which may involve other nutritional support as well as lifestyle adjustment. Such a problem can take many months to fully fix, since it generally took years to develop. Medical treatment of A-fib is directed at drugs that sedate the cardiovascular or nervous system and rat poison that is supposed to prevent a stroke, while doing virtually nothing to address the source of the problem.